Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Drug eruption caused by memantine

Ryuichi Saito¹, Yu Sawada¹, Takashi Yamaguchi¹

¹Department of Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan.

Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology

|July 3, 2017

Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Real-world Implementation of Adjuvant Pembrolizumab for High-risk Clear-cell Renal Cell Carcinoma After Surgery.

In vivo (Athens, Greece)·2026

Same author

Ureteral Orifice Stricture After Transurethral Resection of Bladder Tumors Involving the Ureteral Orifice or Adjacent Area: Clinical Course and Outcomes.

In vivo (Athens, Greece)·2026

Same author

A Nomogram Predicts the Need for Internal Iliac Vein Dissection During Renal Transplantation: A Multicenter Collaborative Study.

Transplantation proceedings·2026

Same author

Early Progressive Disease During Nivolumab Plus Ipilimumab Therapy Predicts Poor Survival in Japanese Patients with Advanced Renal Cell Carcinoma: A Single-Center 12-Week Landmark Study.

Research and reports in urology·2026

Same author

Real-world Delivery and Outcomes of Intravesical BCG for Non-muscle-invasive Bladder Cancer.

Anticancer research·2026

Same author

Early Progressive Disease Predicts Poor Outcomes of Second-line VEGFR Tyrosine Kinase Inhibitor Therapy After First-line Nivolumab Plus Ipilimumab in Advanced Renal Cell Carcinoma.

Anticancer research·2026